Valiant Organics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
VALIANTORG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Organics Limited reported its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results on August 13, 2025. Standalone revenue from operations grew to Rs. 20,440.64 lakhs from Rs. 16,791.70 lakhs in Q1 FY25, a jump of about 21.7% year-on-year. Net profit swung to Rs. 757.84 lakhs from a loss of Rs. 44.19 lakhs a year earlier, with EPS improving to Rs. 2.71 from Rs. (0.16). Consolidated net profit was Rs. 820.28 lakhs (vs. loss of Rs. 61.99 lakhs), with consolidated EPS at Rs. 2.93. The auditor Gokhale & Sathe issued a clean limited review report with no qualifications. The board also approved the appointment of M/s. Mehta & Mehta as Secretarial Auditor for five years (FY26–FY30), subject to shareholder approval. A related-party manufacturing arrangement with Aarti Pharmalabs Ltd at the AJ4 division (effective May 15, 2025) was also disclosed.
Strong operational turnaround — revenue grew over 20% and the company returned to profit after a loss in the same quarter last year, which is likely to be viewed positively by shareholders. The new related-party contract with Aarti Pharmalabs adds incremental business, but the market may also watch margins and finance costs (Rs. 600.17 lakhs) for sustainability of the recovery.